Opthea (ASX:OPT) completed its drug product process performance qualification campaign for its sozinibercept drug candidate to treat wet age-related macular degeneration, demonstrating its ability to consistently manufacture the candidate at a commercial scale, according to a Wednesday Australian bourse filing.

The campaign consisted of the production of three consecutive commercial-scale drug product batches.

This was required to further validate its manufacturing process in preparation for a potential biologics license application filing, as well as the commercialization of sozinibercept, in the first half of 2026.

The firm's shares fell 5% in early trading on Wednesday.